Jane Moore

, MLT, ART, BSc

Assistant Professor (Part-time)
Pathology and Molecular Medicine

McMaster University
3H42 Health Sciences Centre
905-525-9140 , ext. 22414
moorej@mcmaster.ca

Education and Professional Standing

• BSc, Life Science, McMaster University, 2000
• ART, Immunohematology, Canadian Society of Laboratory Technologists, 1980
• MLT, Mohawk College, 1975

---

Interests

Research Focus

My main research focus is platelet immunology, with special interest in thrombocytopenic purpura (TCP, a rare platelet disorder.  While this illness has been associated with an enzyme that cleaves von Willebrand factor, it has also been theorized that there may be other causes linked to manifestation of TCP in patients.  My lab investigates these possible other factors.

Furthermore, my lab investigates heparin-induced thrombocytopenia (HIT) reactions in patients who have received heparin for cardiac or skeletal surgical procedures.  A very small fraction patients given heparin for these procedures develop antibodies against heparin, and result in an adverse reaction.

Funding for this research is provided by the Heart and Stroke Foundation.

---

Team Members

Lab Supervisors

Dr. J. Kelton, Dr. D.Arnold

Post Doctoral Students

Dr. I. Nazi

Other Members

Rumi Clare, Diana Moffatt, Denise Neutel, Jun Santos, Carol Smith, Jim Smith

Selected Publications

• Warkentin TE, Sheppard JA, Moore JC, Cook RJ, Kelton JG. Studies of the immune response in heparin-induced thrombocytopenia. Blood. 2009 May 14; 113(20): 4963-9.
• Warkentin TE, Sheppard JI, Moore JC, Siquoin CS, Kelton JG. Quantitative interpretation of optical dentisty meatusrements using PF4-dependent enzyme immunoassays. J Thromb Haemost. 2008; 8: 1304-12
• Carrier M, Rodger MA, Fergusson D, Coucette S, Kovacs MJ, Moore JC, Kelton JG, Knoll GA. Increased mortality in hemodialysis patients havinf specific antibodies to the platelet factor 4-heparin complex. Kidney Int. 2008; 73: 213-9.
• Moore JC, Arnold DM, Warkentin TE, Warkentin AE, Kelton JG. An algorithm for resolving ‘indetrminate’ test results in the platelet serotonin release assay for investigation of heparin-induced thrombocytopenia. J Thromb Haemost. 2008; 6: 1595-7.
• Price EA, Hayward CP, Moffat KA, Moore JC, Warkentin TE, Zehnder JL. Laboratory testing for heparin-induced thrombocytopenia is inconsistent in North America: a survey of North American specialized coagulation laboratories. Thromb Haemost. 2007; 98: 1357-61.
• Carrier M, Knoll GA, Kovacs MJ, Moore JC, Fergusson D, Rodger MA. The prevalence of antibodies to the platelet factor 4-heparin complex and association with access thrombosis in patients on chronic hemodialysis.  Thromb Res. 2007; 120: 215-20.
• Moore JC, Arnold DM, Leber BF, Clare R, Molnar GJ, Kelton JG. Intravenous immunoglobulin as an adjunct to plasma exchange for the treatment of chronic thrombotic thrombocytopenic purpura. Vox Sang. 2007; 93: 173-5.
• Basch M, Gustafson DL, Holden SN, O’Bryant CL, Gore L, Witta S, Schultz MK, Morrow M, Levin A, Creese BR, Kangas M, Roberts K, Nguyen T, Davis K, Addison RS, Moore JC, Eckhardt SG. A phase I biological and pharmoacologuc study of the heparanase inhinitor PI-88 in patients with advanced solid tumors. Clin Cancer Res. 2006; 12: 5471-80.
• Warkentin TE, Sheppard JA, Moore JC, Moore KM, Sigouin CS, Kelton JG.  Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? J Lab Clin Med.  2005; 146: 341-6.
• Warkentin TE Cook RJ, Marder VJ, Sheppard JA, Moore JC, Eriksson BI, Greinacher A, Kelton JG. Anti-platelet factor 4/heparin antibodies in orthopaedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood. 2005; 106: 3791-6.